Coeptis Therapeutics Holdings's top three insider shareholders as of March 23, 2026 are Chris Calise (Director, 368.74K shares), David Mehalick (Ceo And President, 330.19K shares), Daniel Alexander Yerace (Vp Operations, 70.53K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Capital, Llc Glazer | 0 | 48,221 | 26 May, 2021 | |
| Circle Investments, Llc Harraden | 0 | 21,457 | 06 May, 2022 | |
| Chris Calise | 368,741 | 0 | 13 Feb, 2026 | |
| David Mehalick | Ceo And President | 330,192 | 0 | 13 Feb, 2026 |
| Daniel Alexander Yerace | Vp Operations | 70,531 | 0 | 13 Feb, 2026 |
| Christine Elise Sheehy | Vp Compliance And Secy | 64,031 | 0 | 13 Feb, 2026 |
| Brian Cogley | Chief Financial Officer | 22,500 | 0 | 13 Feb, 2026 |
| Gene Salkind | 13,161 | 0 | 13 Feb, 2026 | |
| Christopher P. Cochran | 8,950 | 0 | 13 Feb, 2026 | |
| Philippe Deschamps | 8,950 | 0 | 13 Feb, 2026 | |
| Tara Desilva | 8,950 | 0 | 13 Feb, 2026 | |
| Gene Salkind | 0 | 202 | 30 Aug, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 11 Feb, 2026 | Christopher P. Cochran | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Daniel Alexander Yerace | Common stock | A | 10,000 | $10.41 | 70,531 | D | M |
| 11 Feb, 2026 | Gene Salkind | Common stock | A | 5,700 | $10.56 | 13,161 | D | M |
| 11 Feb, 2026 | Philippe Deschamps | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Christine Elise Sheehy | Common stock | A | 1,000 | $10.56 | 64,031 | D | M |
| 11 Feb, 2026 | Chris Calise | Common stock | A | 5,700 | $10.56 | 368,741 | D | M |
| 11 Feb, 2026 | David Mehalick | Common stock | A | 148,875 | $7.05 | 330,192 | D | M |
| 11 Feb, 2026 | Tara Desilva | Common stock | A | 5,700 | $10.56 | 8,950 | D | M |
| 11 Feb, 2026 | Brian Cogley | Common stock | A | 10,000 | $10.56 | 22,500 | D | M |
| 11 Feb, 2026 | Christine Elise Sheehy | Common Stock | A | 12,500 | $0.00 | 64,031 | D | A |
| 11 Feb, 2026 | David Mehalick | Common Stock | A | 51,250 | $0.00 | 330,192 | D | A |
| 11 Feb, 2026 | Philippe Deschamps | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Brian Cogley | Common Stock | A | 12,500 | $0.00 | 22,500 | D | A |
| 11 Feb, 2026 | Chris Calise | Common stock | A | 3,250 | $0.00 | 368,741 | D | A |
| 11 Feb, 2026 | Tara Desilva | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Christopher P. Cochran | Common Stock | A | 3,250 | $0.00 | 8,950 | D | A |
| 11 Feb, 2026 | Daniel Alexander Yerace | Common Stock | A | 20,000 | $0.00 | 70,531 | D | A |
| 11 Feb, 2026 | Gene Salkind | Common Stock | A | 3,250 | $0.00 | 13,161 | D | A |
| 04 Mar, 2025 | Philippe Deschamps | Non-qualified Stock Options (right to buy) | A | 5,700 | - | 8,950 | D | A |
| 04 Mar, 2025 | Chris Calise | Non-qualified Stock Options (right to buy) | A | 5,700 | - | 8,950 | D | A |